OBJECTIVE: Ki-67 is a proliferation-associated nuclear antigen and is expressed in all cycling cells except for resting cells in the G0-phase. PCNA is an acidic nuclear protein and has been recognized as a histologic marker for the G1/S phase in the cell cycle. Ki-67and PCNA labeling indices are considered to reflect cell proliferation, particularly, growth fraction. The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa. METHODS: Human prostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Then, the association of Ki-67 and PCNA expression with clinical grading of PCa was analyzed by immunohistochemistry staining. RESULTS: The ratios of PCNA and Ki-67 expression levels in LNCaP and PC-3 were higher (P < 0.05, P < 0.001) than that in HuPEC. The two markers were differentially expressed in three tissues and showed increased expression in PCa (P < 0.05) and BPH (P < 0.05), relative to human normal prostate tissues. Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P < 0.05). The increase of Ki-67 was greater than that of PCNA. Expression of the two markers increased after different grading of PCa cases. The values of Ki-67/PCNA were: 0.073 in grade I PCa tissues, 0.119 in grade IIa PCa tissues, 0.141 in grade IIa PCa tissues, 0.234 in grade III PCa tissues. CONCLUSION: The combination of Ki-67 and PCNA, specific proliferative markers of PCa, may improve the accuracy of early diagnosis of prostatic cancer.
OBJECTIVE:Ki-67 is a proliferation-associated nuclear antigen and is expressed in all cycling cells except for resting cells in the G0-phase. PCNA is an acidic nuclear protein and has been recognized as a histologic marker for the G1/S phase in the cell cycle. Ki-67and PCNA labeling indices are considered to reflect cell proliferation, particularly, growth fraction. The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa. METHODS:Humanprostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR). Then, the association of Ki-67 and PCNA expression with clinical grading of PCa was analyzed by immunohistochemistry staining. RESULTS: The ratios of PCNA and Ki-67 expression levels in LNCaP and PC-3 were higher (P < 0.05, P < 0.001) than that in HuPEC. The two markers were differentially expressed in three tissues and showed increased expression in PCa (P < 0.05) and BPH (P < 0.05), relative to human normal prostate tissues. Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P < 0.05). The increase of Ki-67 was greater than that of PCNA. Expression of the two markers increased after different grading of PCa cases. The values of Ki-67/PCNA were: 0.073 in grade I PCa tissues, 0.119 in grade IIa PCa tissues, 0.141 in grade IIa PCa tissues, 0.234 in grade III PCa tissues. CONCLUSION: The combination of Ki-67 and PCNA, specific proliferative markers of PCa, may improve the accuracy of early diagnosis of prostatic cancer.
Authors: Zongqing Tan; Matthew Wortman; Kelsey L Dillehay; William L Seibel; Chris R Evelyn; Shanna J Smith; Linda H Malkas; Yi Zheng; Shan Lu; Zhongyun Dong Journal: Mol Pharmacol Date: 2012-03-07 Impact factor: 4.436
Authors: Bilal Bin Hafeez; Weixiong Zhong; Ala Mustafa; Joseph W Fischer; Olya Witkowsky; Ajit K Verma Journal: Carcinogenesis Date: 2012-09-13 Impact factor: 4.944
Authors: Antoun Toubaji; Siobhan Sutcliffe; Alcides Chaux; Kristen Lecksell; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto Journal: Hum Pathol Date: 2012-05-02 Impact factor: 3.466
Authors: K R Keshari; H Tsachres; R Iman; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz Journal: NMR Biomed Date: 2011-07 Impact factor: 4.044
Authors: Bilal Bin Hafeez; Weixiong Zhong; Jamey Weichert; Nancy E Dreckschmidt; Mohammad Sarwar Jamal; Ajit K Verma Journal: Cancer Res Date: 2011-03-15 Impact factor: 12.701
Authors: M Veronica Clavijo Jordan; Su-Tang Lo; Shiuhwei Chen; Christian Preihs; Sara Chirayil; Shanrong Zhang; Payal Kapur; Wen-Hong Li; Luis M De Leon-Rodriguez; Angelo J M Lubag; Neil M Rofsky; A Dean Sherry Journal: Proc Natl Acad Sci U S A Date: 2016-08-25 Impact factor: 11.205
Authors: Mikhail G Dozmorov; Robert E Hurst; Daniel J Culkin; Bradley P Kropp; Mark Barton Frank; Jeanette Osban; Trevor M Penning; Hsueh-Kung Lin Journal: Prostate Date: 2009-07-01 Impact factor: 4.104